Journal
CLINICAL AND EXPERIMENTAL IMMUNOLOGY
Volume 151, Issue 2, Pages 231-234Publisher
BLACKWELL PUBLISHING
DOI: 10.1111/j.1365-2249.2007.03559.x
Keywords
clinical trials; first-in-man; immunotherapy; phase 1; TGN1412
Categories
Funding
- Wellcome Trust [074731] Funding Source: Medline
Ask authors/readers for more resources
Current immunology research is generating many new approaches to immunotherapy. However, the recent disaster surrounding the testing of TGN1412, has unsettled regulators and the pharmaceutical industry regarding new immunotherapies and highlighted the complexities of conducting clinical trials with agents that target the immune system. Here we discuss the critical role for immunologists in ensuring that the development of new immunotherapies continues.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available